Strategic Initiative

Slingshot members are tracking this corporate initiative:

BioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor Use in CAR T Cell Therapies

Source Link:: http://investors.biolifesolutions.com/2016-07-11-BioLife-Solutions-Executes-10-Year-Supply-Agreement-with-Kite-Pharma-for-CryoStor-Use-in-CAR-T-Cell-Therapies

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

KITE

100%

BLFS

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details BioLife Solutions has entered into a ten year supply agreement with Kite Pharma, a leading developer of chimeric antigen receptor (CAR) and T cell receptor (TCR) products for various cancers.The agreement provides for Kite's supply of BioLife's CryoStor clinical grade freeze media for cells and tissues, which is embedded in Kite's manufacturing process for KTE-C19, a CAR T cell therapy currently in four clinical trials for various cancers.

http://investors.bio...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Jul 11, 2016

Projected Implementation:

Q1, 2016

Relevance Tracked Until:

Q3, 2016

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Car T Cell Therapy, Cryostor, Cryopreservation Freeze Media, Tissue Hypothermic Storage, T Cell Receptor, Cancer